Previous work in the DSS colitis model suggests that the PPAR-γ agonist rosiglitazone ameliorates colitis by activating PPAR-γ signaling in macrophages (22), whereas epithelial Pparg expression is not required for its anti-inflammatory activity (21). Here, PPARG is linked to colitis.